[go: up one dir, main page]

MX2022004566A - Agonista del receptor de taquiquinina 2 (tacr2). - Google Patents

Agonista del receptor de taquiquinina 2 (tacr2).

Info

Publication number
MX2022004566A
MX2022004566A MX2022004566A MX2022004566A MX2022004566A MX 2022004566 A MX2022004566 A MX 2022004566A MX 2022004566 A MX2022004566 A MX 2022004566A MX 2022004566 A MX2022004566 A MX 2022004566A MX 2022004566 A MX2022004566 A MX 2022004566A
Authority
MX
Mexico
Prior art keywords
tacr2
agonists
agonist
relates
obesity
Prior art date
Application number
MX2022004566A
Other languages
English (en)
Inventor
Zachary Gerhart-Hines
Jakob Bondo Hansen
Thue W Schwartz
Original Assignee
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Copenhagen filed Critical Univ Copenhagen
Publication of MX2022004566A publication Critical patent/MX2022004566A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a agonistas de Tacr2, tal como agonistas peptídicos de Tacr2 y a métodos de uso de los mismos para el tratamiento de resistencia a la insulina, obesidad y/o diabetes. La descripción también se refiere al uso de dichos agonistas de Tacr2 para el aumento del consumo de energía en un individuo.
MX2022004566A 2019-10-17 2019-10-17 Agonista del receptor de taquiquinina 2 (tacr2). MX2022004566A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/078201 WO2021073742A1 (en) 2019-10-17 2019-10-17 Agonist of tacr2

Publications (1)

Publication Number Publication Date
MX2022004566A true MX2022004566A (es) 2022-07-21

Family

ID=68392943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004566A MX2022004566A (es) 2019-10-17 2019-10-17 Agonista del receptor de taquiquinina 2 (tacr2).

Country Status (10)

Country Link
US (1) US20240124524A1 (es)
EP (1) EP4045072A1 (es)
JP (1) JP2023506117A (es)
KR (1) KR20220084035A (es)
CN (1) CN114599382A (es)
AU (1) AU2019470336B9 (es)
CA (1) CA3151979A1 (es)
IL (1) IL291502A (es)
MX (1) MX2022004566A (es)
WO (1) WO2021073742A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231952A1 (es) * 2020-11-09 2023-12-06 Embark Biotech Aps Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830863A (en) * 1988-06-20 1998-11-03 Merrell Pharmaceuticals Inc. Neurokinin A antagonists
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
WO2005101009A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
US20090312255A1 (en) * 2006-12-14 2009-12-17 The Hospital For Sick Children Stimulation of trpv1+ sensory neurons to control beta-cell stress and islet inflammation in diabetes
MX2012005015A (es) * 2009-10-30 2012-06-12 Prometheus Lab Inc Metodos para diagnosticar sindrome de intestino irritable.
WO2011133948A2 (en) * 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US11278549B2 (en) * 2013-02-15 2022-03-22 Mcmaster University Method of treating obesity
RU2727022C2 (ru) * 2013-10-01 2020-07-17 Сфинготек Гмбх Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
US20170065663A1 (en) * 2014-05-02 2017-03-09 New Amsterdam Sciences Substance and method for treating influenza
WO2017015760A1 (en) * 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin

Also Published As

Publication number Publication date
IL291502A (en) 2022-05-01
US20240124524A1 (en) 2024-04-18
JP2023506117A (ja) 2023-02-15
AU2019470336B9 (en) 2025-03-20
WO2021073742A1 (en) 2021-04-22
CN114599382A (zh) 2022-06-07
CA3151979A1 (en) 2021-04-22
AU2019470336A1 (en) 2022-04-28
EP4045072A1 (en) 2022-08-24
KR20220084035A (ko) 2022-06-21
AU2019470336B2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MX2021011728A (es) Agonista beta adrenergico y metodos de uso de este.
MX2020000734A (es) Enantiómeros s de beta-hidroxibutirato y butanodiol, y métodos para usarlos.
ES2553593T3 (es) Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2
UY37568A (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
AR102712A1 (es) Agonistas parciales del receptor de insulina
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
NZ740644A (en) Glucagon receptor agonists
CL2018001695A1 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
AR099912A1 (es) Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
EP3589303A4 (en) Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
AR092076A1 (es) Proteinas homodimericas
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
UY35340A (es) Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
BR112019006865A2 (pt) caspases induzíveis e métodos para uso
UY34859A (es) Análogos peptídicos de la exendina 4.
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
BR112016023607A2 (pt) uso médico de compostos de artemisinina e agonistas de gefirina
CL2020001605A1 (es) Anticuerpos anti alfa-sinucleína.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
CR20200061A (es) Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)